Medivation Inc (MDVN)

81.44
0.02 0.02
NASDAQ : Health Care
Prev Close 81.42
Open 81.44
Day Low/High 81.43 / 81.48
52 Wk Low/High 26.41 / 63.34
Volume 7.20M
Avg Volume 4.26M
Exchange NASDAQ
Shares Outstanding 165.93M
Market Cap 13.51B
EPS 1.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
Sanofi's Likely Sweetener for Medivation Panned

Sanofi's Likely Sweetener for Medivation Panned

The French drugmaker is reportedly thinking about including a CVR in its $9.3 billion bid for Medivation, but the move is unlikely to be enough to entice the target's shareholders.

BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced

BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced

While some say Sanofi could make a bid for BioMarin, analysts aren't so convinced.

MEDIVATION INVESTIGATION ALERT - Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breaches Of Fiduciary Duty - MDVN

MEDIVATION INVESTIGATION ALERT - Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breaches Of Fiduciary Duty - MDVN

Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Medivation, Inc.

Medivation Urges Shareholders to Reject Sanofi Proposal

Medivation Urges Shareholders to Reject Sanofi Proposal

In a battle of letters in preparation for an Aug. 2 vote, the biotech company is resisting the French drugmaker's $9.3 billion overture, and analysts agree with the move.

(Graphic: Business Wire)

(Graphic: Business Wire)

Medivation, Inc. (NASDAQ:MDVN) today announced that it has filed with the Securities and Exchange Commission ("SEC") a definitive Consent Revocation Statement.

MEDIVATION (MDVN) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breach Of Fiduciary Duty

MEDIVATION (MDVN) SHAREHOLDER ALERT - Andrews & Springer LLC Is Investigating Medivation, Inc. For Potential Breach Of Fiduciary Duty

Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against Medivation, Inc.

The Ingenious Moneymaking Method of the World's Super Investors: Buffett, Lynch, Icahn

The Ingenious Moneymaking Method of the World's Super Investors: Buffett, Lynch, Icahn

Concerned about the market's volatility? Here's a time-tested strategy that leverages risk for market-thumping gains.

Valeant's Share Price Tumbles, Even as Papa Reiterates Plans for Divestitures

Valeant's Share Price Tumbles, Even as Papa Reiterates Plans for Divestitures

Some analysts say the company could be worth a second look, though, as they expect top line growth.

Insider Trading Alert - MYL, PKD And MDVN Traded By Insiders

Insider Trading Alert - MYL, PKD And MDVN Traded By Insiders

Stocks with insider trader activity include MYL, PKD and MDVN

Medivation Pulls Up Shareholder Drawbridge as Sanofi Battle Looms

Medivation Pulls Up Shareholder Drawbridge as Sanofi Battle Looms

The cancer drug maker moves to lock new shareholders out of an upcoming vote.

Medivation Sets Record Date For Sanofi's Proposed Consent Solicitation

Medivation Sets Record Date For Sanofi's Proposed Consent Solicitation

Medivation, Inc. (NASDAQ:MDVN) today confirmed that it has received a request from Sanofi to establish a record date to determine which of the Company's stockholders are eligible to participate in the proposed solicitation...

Biotech M&A Waking Up After Long Nap

Biotech M&A Waking Up After Long Nap

The uptick in the small- and mid-cap space bodes well for future capital appreciation.

Medivation Fires Back Following Sanofi's Board Proposal

Medivation Fires Back Following Sanofi's Board Proposal

The biopharmaceutical company rejects Sanofi's $9.3 billion bid once again.

Medivation Files Preliminary Consent Revocation Statement

Medivation Files Preliminary Consent Revocation Statement

Medivation, Inc. (NASDAQ:MDVN) today announced that it has filed a preliminary Consent Revocation Statement with the Securities and Exchange Commission in response to Sanofi's preliminary consent solicitation statement...

European Markets End in Positive Territory; Rally for Second Day

European Markets End in Positive Territory; Rally for Second Day

Bank stocks once again pull up European indices

Pfizer Wants to Be Seen as an Oncology Powerhouse

Pfizer Wants to Be Seen as an Oncology Powerhouse

The president and global manager of Global Oncology says Pfizer has a nice recipe to win in oncology.

Sanofi Moves to Oust Medivation Board

Sanofi Moves to Oust Medivation Board

The French pharma goes hostile with its $9.3 billion bid, but promises an improved offer if Medivation enters talks.

Medivation Urges Stockholders To Reject Sanofi's Attempt To Replace Medivation Board Of Directors

Medivation Urges Stockholders To Reject Sanofi's Attempt To Replace Medivation Board Of Directors

Medivation, Inc. (NASDAQ: MDVN) today urged its stockholders to reject Sanofi's attempt to replace the company's entire Board of Directors with hand-picked nominees through a proposed consent solicitation, which Medivation...

'Mad Money' Lightning Round: I'm Flying With Delta

'Mad Money' Lightning Round: I'm Flying With Delta

Cramer says he has liked Taser for ages but thinks Sarepta Therapeutics is a battleground stock.

Jim Cramer's 'Mad Money' Recap: These Catalysts Pushed the Market Up Today

Jim Cramer's 'Mad Money' Recap: These Catalysts Pushed the Market Up Today

Even chatter of a Federal Reserve interest rate hike didn't push stocks down, Cramer says.

2 Promising Biopharmas Reach Key Junctures

2 Promising Biopharmas Reach Key Junctures

FDA decision will impact Relypsa's buyout potential while Aritana won't stay this undervalued.

Biotech Is Showing Some Bargains

Biotech Is Showing Some Bargains

It is hard to see much growth in the market overall, until earnings growth returns.

Pfizer Beats Allergan to Eczema Drugmaker Anacor for $5.2B

Pfizer Beats Allergan to Eczema Drugmaker Anacor for $5.2B

The deal gives the acquirer access to Crisaborole and denies the excema drug to its ex-merger partner.

Medivation Shares Stand Pat Amid Further Bid Speculation

Medivation Shares Stand Pat Amid Further Bid Speculation

Sanofi is said to be nominating eight people to Medivation's board.

It's Macy's Fault Sales Are Down, Not Shoppers'

It's Macy's Fault Sales Are Down, Not Shoppers'

Mark Luschini, chief equity strategist for Janney Montgomery Scott, says the retailers' problems are its own doing.

Global Pharma Players Likely to Flock to Medivation

Global Pharma Players Likely to Flock to Medivation

AstraZeneca, Bayer, Eli Lilly and Merck are just a few of the names that may join a bidding war for the cancer drug maker, analysts say.

Medivation (MDVN) Stock Surges, Will Explore Sale

Medivation (MDVN) Stock Surges, Will Explore Sale

Medivation (MDVN) stock is higher in mid-afternoon trading on Monday, as the drug maker will reportedly explore a sale following takeover interest.

Analysts' Actions -- Fidelity, Medivation, Occidental, Paccar and More

Analysts' Actions -- Fidelity, Medivation, Occidental, Paccar and More

Here are Monday's top research calls, including upgrades for Fidelity National, Medivation and Paccar, and a downgrade for Occidental Petroleum.

TV Lives; Growth, Growth, Who's Got the Growth?: Jim Cramer’s Best Blogs

TV Lives; Growth, Growth, Who's Got the Growth?: Jim Cramer’s Best Blogs

Jim Cramer comes to praise TV, not to bury it, and wonders where all the growth has gone.

2 Longs and 2 Shorts to Watch in the Stock Market

2 Longs and 2 Shorts to Watch in the Stock Market

Here are two longs and two shorts to watch as the stock market presents both technical breakout and breakdown opportunities.